Summit Therapeutics Total Liabilities

As of the most recent data (June 2026), SMMT shows a total liabilities of $120M. That compares with $65M in the prior-year period — up 89.2% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, SMMT's total liabilities is now $120M (was $65M) — a 89.2% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Summit Therapeutics is outperforming or lagging.

Tracking SMMT's total liabilities over time shows whether Summit Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $120M That compares with $65M in the prior-year period — up 89.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total liabilities page, Stockcircle has Summit Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total liabilities (currently $120M) with ownership activity and broader fundamentals.